Agents for neutron capture therapy

Inactive Publication Date: 2004-02-05
PHARMACYCLICS
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Absent this property, neutron irradiation would lead to a low rate of capture of neutrons, and lack of selectivity, thus rendering the treatment ineffective.
Unfortunately, .sup.10B does not meet this requirement, as it is not itself selective for tumor tissue.
However, this approach has not been entirely successful, as this boron compound has limited selectivity for tumors, and also poor tumor/blood concentration ratios, which leads to vascular endothelial damage upon radiation, causing damage to the normal brain.
However, this compound has also been found to have poor selectivity for tumors, and additionally has a major limitation in that it is phototoxic.
Gadolinium (Gd) is one such element, as it has a relatively large barns radius (48,800 b); notably, the .sup.157Gd isomer of gadolinium has a barns radius of 254,000 b. However, gadolinium itself poses the threat of ion toxicity, and the early gadolinium chelates prepared for use as MRI imaging agents were not selective for tumors and other targeted tissues.
Additionally, the porphyrins that were suitable fo

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Agents for neutron capture therapy
  • Agents for neutron capture therapy
  • Agents for neutron capture therapy

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of .sup.157Gadolinium Texaphyrin

[0215] .sup.157Gadolinium texaphyrin metal complex was prepared using standard methods previously described in Sessler et al., J. Phys. Chem., vol. 103, pgs. 787-794 (1999) and Young et al., Photochem. Photobiol., vol. 63, pgs. 892-897 (1996). The macrocyclic ligand, 9,10-diethyl-7,12-dihydro-20,21-bis[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]--4,15-dimethyl-3,6:8, 11:13,16-triimino-1,18-benzodiazacycloeicosine-5,14-d-ipropanol hydrochloride (IP-NP2, 2.2 g, 2.39 mmol), was oxidatively metallated using gadolinium(157) nitrate pentahydrate (1.02 g, 2.39 mmol) and triethylamine (3.3 mL, 23.9 mmol) in air-saturated methanol (200 mL) at reflux. After completion of the reaction (as judged by the optical spectrum of the reaction mixture), the deep green solution was cooled to room temperature and the solvent reduced to 150 mL under reduced pressure. The dark green solution was loaded onto a column (8 cm length.times.2.5 cm diameter) of pretreated Amberse

example 2

Determination of Neutron Capture Activity In Vitro Utilizing the V79 Chinese Hamster Cell Survival Assay

[0216] The effect of neutron irradiation on V79 Chinese hamster cells incubated for twelve hours with .sup.157Gd-Tex is determined by a modification of the procedure originally described by Fairchild et al., Cancer Research 50 (1990). Three sets of sample plates of V79 cells are prepared. The first set (control cells) are suspended with 30ppm .sup.157Gd-Tex in growth medium. The second set (washed cells) are suspended with 30ppm .sup.157Gd-Tex in growth medium, then washed 3 times with PBS, trypsinized and harvested with gadolinium from reagents prior to suspension. The third set (ambient cells) are suspended in a 30ppm .sup.157Gd containing medium.

[0217] All of the cells are irradiated within 1-2 hours following suspension in growth medium at a population density of 3.0.times.10.sup.5 cells / ml. The neutron beam fluence rate at the center of the sample is 2.8.times.10.sup.11 n / cm

example 3

Determination of Neutron Capture Activity Utilizing Glioma 261 Cells

[0219] This procedure is a modification of a procedure initially described by Saris et al., Cancer Research, vol. 52 (1992). Glioma 261 tumor fragments are injected approximately 2 mm deep to the dura of the brain in 42 female C57BL / 6 mice. The mice are randomized into 5 groups. The mice in group A receive ???? mg / kg Gd-Tex and 1.2.times.10.sup.12 neutrons / cm.sup.2 resulting in 20 Gy. Group B mice receive 1.2.times.10.sup.12 neutrons / cm.sup.2 resulting in 20 Gy. The mice in group C receive ???? mg / kg Gd-Tex and 10 Gy of photon irradiation. Group D receives ???? mg / kg of Gd-Tex alone. Group E receives no treatment.

[0220] After 5 days (when the tumor is approximately 2 mm), ???? mg / kg of a texaphyrin is administered by intravenous injection (groups A, C and D only). ???? Hours later, the mice in groups A and B are anesthetized and irradiated with a neutron beam of 1.2.times.10.sup.12 neutrons / cm.sup.2 to

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Digital informationaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to view more

Abstract

Compounds, pharmaceutical formulations and methods for use in neutron capture therapy are provided, useful for treating diseases characterized by neoplastic tissue and arteriosclerosis.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner PHARMACYCLICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products